PubMed

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.

Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW.

Ann Intern Med. 2006 Feb 21;144(4):239-48.PMID: 16490909 [PubMed - indexed for MEDLINE]Related articlesFree article

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.

Monegal A, Guañabens N, Suárez MJ, Suárez F, Clemente G, García-González M, De la Mata M, Serrano T, Casafont F, Tome S, Barrios C, Navasa M.

Transpl Int. 2009 Feb;22(2):198-206. Epub 2008 Sep 15. Erratum in: Transpl Int. 2009 Jun;22(6):679. Torne, Santiago [corrected to Tome, Santiago]. PMID: 18796000 [PubMed - indexed for MEDLINE]Related articles

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators.

Lancet. 2009 Apr 11;373(9671):1253-63.PMID: 19362675 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Zolendronic acid prevents bone loss after liver transplantation.

[No authors listed]

Ann Intern Med. 2006 Feb 21;144(4):I37. No abstract available. PMID: 16490906 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.PMID: 17369566 [PubMed - indexed for MEDLINE]Related articles

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.PMID: 17553207 [PubMed - indexed for MEDLINE]Related articles

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Lancet Oncol. 2008 Sep;9(9):840-9. Epub 2008 Aug 19.PMID: 18718815 [PubMed - indexed for MEDLINE]Related articles

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial.

N Engl J Med. 2007 May 3;356(18):1809-22.PMID: 17476007 [PubMed - indexed for MEDLINE]Related articlesFree article

Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R.

Kidney Int. 2003 Mar;63(3):1130-6.PMID: 12631097 [PubMed - indexed for MEDLINE]Related articles

A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.

Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, Crawford BA.

Calcif Tissue Int. 2006 Sep;79(3):138-44. Epub 2006 Sep 11.PMID: 16969592 [PubMed - indexed for MEDLINE]Related articles

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.

BJU Int. 2007 Jul;100(1):70-5.PMID: 17552955 [PubMed - indexed for MEDLINE]Related articles

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.PMID: 16463007 [PubMed - indexed for MEDLINE]Related articles

Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.

J Am Geriatr Soc. 2007 May;55(5):752-7.PMID: 17493196 [PubMed - indexed for MEDLINE]Related articles

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.PMID: 12771706 [PubMed - indexed for MEDLINE]Related articles

Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.

Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J.

Am J Kidney Dis. 2009 May;53(5):856-65.PMID: 19393473 [PubMed - indexed for MEDLINE]Related articles

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.PMID: 18035193 [PubMed - indexed for MEDLINE]Related articles

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.

J Clin Endocrinol Metab. 2004 Jul;89(7):3319-25.PMID: 15240609 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.

Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, Caminis J.

Calcif Tissue Int. 2007 May;80(5):316-22. Epub 2007 Apr 7.PMID: 17417700 [PubMed - indexed for MEDLINE]Related articles

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group.

J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68.PMID: 12359855 [PubMed - indexed for MEDLINE]Related articlesFree article

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.PMID: 17468062 [PubMed - indexed for MEDLINE]Related articles